6Suppliers
2Customers
2Debt Items
12Related Chains

Nkarta, Inc. Suppliers

TickerNameConfidenceEvidence
LICENSORS LICENSORS 92% Payments to the Licensors pursuant to the license agreement include single-digit royalty payments on commercial sales, a portion of any sublicensing revenue, patent expenses, license maintenance fees…
THIRD-PARTY-CONTRACT-MANUFACTURING-SITES THIRD-PARTY-CONTRACT-MANUFACTURING-SITES 90% we currently manufacture clinical supply of NKSTIM cells and the gamma-retrovirus at third-party contract manufacturing sites.
NATIONAL-UNIVERSITY-OF-SINGAPORE NATIONAL-UNIVERSITY-OF-SINGAPORE 80% If our license agreement with National University of Singapore and St. Jude Children’s Research Hospital, Inc. is terminated, we could lose our rights to key components enabling our NK-cell engineeri…
ST-JUDE-CHILDREN-S-RESEARCH-HOSPITAL-INC ST-JUDE-CHILDREN-S-RESEARCH-HOSPITAL-INC 80% If our license agreement with National University of Singapore and St. Jude Children’s Research Hospital, Inc. is terminated, we could lose our rights to key components enabling our NK-cell engineeri…
CRSP CRISPR Therapeutics AG 72% Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as all of the other information co…
CRSP CRISPR Therapeutics AG 72% Reciprocal relationship from CRSP graph: Reciprocal relationship from NKTX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from NKTX graph: Item 1A. Risk Factors. An investmen…

Nkarta, Inc. Customers

TickerNameConfidenceEvidence
CRSP CRISPR Therapeutics AG 72% Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as all of the other information co…
CRSP CRISPR Therapeutics AG 72% Reciprocal relationship from CRSP graph: Reciprocal relationship from NKTX graph: Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should careful…

Nkarta, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
NKTX-DEBT Debt stack $75.0M 90% Market cache reports total debt of $75.0M.
NKTX-DEBT-11283 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.

Nkarta, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Nkarta, Inc..

Nkarta, Inc. Ownership

HolderNameConfidenceEvidence
NKTX-OWNER-RA-CAPITAL-MANAGEMENT-L-P RA CAPITAL MANAGEMENT, L.P. 90% 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 125 tracked holders.

Nkarta, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BDRX Biodexa Pharmaceuticals Plc 100.00 2
ACET Adicet Bio, Inc. 100.00 2
CELU Celularity Inc. 100.00 2
MGX Metagenomi Therapeutics, Inc. 100.00 2
VRTX Vertex Pharmaceuticals Incorporated 100.00 2
VERTEX VERTEX 100.00 2
GLAXF GSK plc 50.00 2
JNJ Johnson & Johnson 50.00 2
PRME Prime Medicine, Inc. 50.00 2
GSK GSK plc 50.00 2
SIRIUS SIRIUS 50.00 2
CRSP CRISPR Therapeutics AG 38.88 1 ['customer', 'supplier']